Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Satraplatin is an oral platinum analog that was tested (in combination with prednisone) in a multinational, double-blind, randomized, placebo-controlled, Phase III clinical trial in patients with metastatic castrate-refractory prostate cancer (CRPC) who had progressed after one prior chemotherapy regimen.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, satraplatin | Leave a Comment »
A new review in BJU International — available in full on the Web through the UroToday web site — provides a detailed review of the currently available data on the use of robot-assisted laparoscopic prostatectomy (RALP) for the treatment of localized prostate cancer.
Filed under: Management, Treatment | Tagged: RALP, robot-assisted laparoscopic prostatectomy | 1 Comment »
A new study by an international team of researchers has further endorsed the value of regular exercise and activity in the long-term prevention of prostate cancer.
Filed under: Prevention, Uncategorized | Tagged: exercise, Prevention | 3 Comments »
A number of physicians and patients have believed for years that so-called “triple” androgen blockade (ADT3) is a more effective option than an LHRH alone or combined androgen deprivation in the treatment of men with advanced prostate cancer. However, the clinical evidence supporting this belief has been limited.
Filed under: Management, Treatment | Tagged: ADT3, bicalutamide, dutasteride, TARP | 4 Comments »
… is not going to be “coming soon to a urologist’s office near you” … but it has now been carried out on a thoroughly well-informed physician-patient at the University of Colorado.
Filed under: Management, Treatment | 9 Comments »
We may tend to think that the European nations, with their varied types of “nationalized” health care system, have overcome the economic health care disparities so evident in nations like the USA, where the ability of pay for and obtain high quality insurance coverage has major impact on access to health care.
Filed under: Diagnosis, Management, Uncategorized | Tagged: outcome, socioeconomic status | Leave a Comment »
There is no doubt that transperineal, template-guided mapping biopsies (TTMBs) can find prostate cancer where more traditional 8- or 12-core transrectal ultrasound (TRUS)-guided biopsies often don’t.
Filed under: Diagnosis | Tagged: biopsy, Diagnosis, mapping | 3 Comments »
The “New” Prostate Cancer InfoLink is by no means the first media outlet to have commented on the potential conflict between the idea of comparative effectiveness research (in large numbers of patients) and the the principles of personalized medicine. But we are pleased to see Dr. Francis Collins, the new director of the National Institutes [...]
Filed under: Drugs in development, Uncategorized | Tagged: comparative effectiveness, personalized medicine | 1 Comment »
I suppose it’s all a matter of opinion … but for those who are interested there is critical news today from Noo Joizy
Filed under: Uncategorized | 1 Comment »
According to a media release this morning, the global pharmaceutical company Astellas has licensed rights to commercialize Medivation’s investigational prostate cancer drug MDV3100.
Filed under: Drugs in development | Tagged: MDV3100 | Leave a Comment »
It may not be a cure for prostate cancer (or even a cure for any cancer) but scientists at the University of Rochester think they may have been able to work out why a rodent called the “naked mole rat” never gets cancer
Filed under: Uncategorized | Tagged: gene, mole rat, p16 | 3 Comments »
An article in this week’s New England Journal of Medicine has argued that an earlier report, postulating the monoclonal origin of lethal metastatic prostate cancer, increases the justification for focal therapy for early stage prostate cancer.
Filed under: Management, Treatment | Tagged: focal therapy, origin | 3 Comments »
There are three pathological subclassifications of prostate cancer that is confined to the prostate: T2a disease (cancer confined to one half of either the left or right lobe or side of the prostate), T2b disease (cancer that is found throughout one lobe or side of the prostate) and T2c disease (cancer that is evident in [...]
Filed under: Management | Tagged: staging | 1 Comment »
Swedish research studies have long been on the “cutting edge” for understanding issues related to screening and early stage tretament for prostate cancer. It is possible that a new study by Holmström et al. may prove to be no exception to this historic experience..
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening | 1 Comment »
With the increasing acceptance of active surveillance as a management strategy for men initially diagnosed with low-risk prostate cancer, it is increasingly important to have a detailed understanding of how these men fare over time, most particularly among those who have subequent progression that needs treatment.
Filed under: Management, Treatment | Tagged: active surveillance, pathology, radical prostatectomy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site